PureTech notes positive results from Shionogi's EndeavorRx ADHD trial | Finance News shareprices.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from shareprices.com Daily Mail and Mail on Sunday newspapers.
PureTech Health PLC on Tuesday noted that its founded entity, Akili Inc, has announced positive results from a phase 3 clinical trial of EndeavorRx for children with attention deficit hyperactivity.
Apnimed to Participate in the Upcoming Evercore ISI 2024 Emerging Biotech Conference streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced the first peer-reviewed publication of the Phase 3 portion of its pivotal, double-blind, randomized, placebo-controlled.